Inflammation‐mediated drug interactions of olokizumab and cytochrome P450 activities in patients with rheumatoid arthritis

Documenti analoghi

• Quantitative prediction of intravenous drug interactions caused by cytochromes P450 inhibitors and inducers
  di: Vianney Tuloup, et al.
  Pubblicazione: (2026)
• Drug–drug interaction profile of ritlecitinib as perpetrator and victim through cytochrome P450
  di: Vivek S. Purohit, et al.
  Pubblicazione: (2025)
• Artemisinins in autoimmune diseases: effects and mechanisms in systemic lupus erythematosus and rheumatoid arthritis
  di: Fanchao Zhou, et al.
  Pubblicazione: (2025)
• A scoping review of disease‐modifying antirheumatic drug nonadherence in rheumatoid arthritis: Measurement, prevalence and implications for clinical practice
  di: Lauren Fraser, et al.
  Pubblicazione: (2025)
• Trajectory of lipid profiles in rheumatoid arthritis patients receiving tofacitinib: Evidence from the prospective CENTRA cohort
  di: Hong Huang, et al.
  Pubblicazione: (2026)